CRO Sector May Accelerate Recovery in H2 as Innovative Drug Projects See Rising Quotes

The signal here is that demand for external R&D services is firming, not just in volume but in pricing power, which suggests the recovery is moving beyond utilization into margin improvement. That matters because it implies pharma clients are committing to pipelines despite broader biotech funding volatility, a shift that could make CRO earnings more predictable. The open question is whether quote increases stick as capacity tightens or if competitive pressures cap the upside, so watching order conversion rates and backlog visibility will be key.